FMFumiyoshi Morikawa

Fumiyoshi Morikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fumiyoshi Morikawa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Electroconvulsive therapy for dementia with Lewy bodies: A systematic review and Japanese multicenter survey

    by Hiroshige Fujishiro, Kuniyuki Iwata-Endo, Ryota Kobayashi, Fumiyoshi Morikawa, Manabu Ikeda


  • Evaluating Electroconvulsive Therapy for Dementia With Lewy Bodies, Including the Prodromal Stage: A Retrospective Study on Safety and Efficacy

    by Fumiyoshi Morikawa, Ryota Kobayashi, Tomonori Murayama, Shota Fukuya, Kazuki Tabata, Hiroshige Fujishiro, Michihiro Nakayama, Juichiro Naoe

    Objectives: Managing symptoms, notably psychiatric symptoms, in dementia with Lewy bodies (DLB) is complex, affecting both patients and caregivers. People with DLB often react poorly to antipsychotics, limiting treatment options. Although electroconvulsive therapy (ECT)'s potential for DLB is acknowledged, evidence is scarce owing to limited studies. This study investigated ECT's effectiveness and safety for DLB and prodromal DLB with antecedent psychiatric symptoms.Methods: This retrospective study investigated people with DLB (N = 12) and mild cognitive impairment (MCI) with LB (N = 13), a prodromal form of DLB, who underwent ECT for psychiatric symptoms and had abnormal findings confirmed using dopamine transporter single‐photon emission computed tomography and 123I‐metaiodobenzylguanidine myocardial scintigraphy. We reviewed these patients' medical records and determined the severity of psychotic symptoms before and 1 week after the final ECT session with the Clinical Global Impressions Severity Scale (CGI‐S). Improvement in psychotic symptoms was evaluated approximately 1 week after the final ECT session using the CGI Improvement Scale (CGI‐I). Additionally, we assessed cognitive function and dementia severity before and after ECT, as well as any adverse events caused by ECT.Results: ECT significantly improved psychiatric symptoms, as assessed using the CGI‐S, with CGI‐I reports in the order of 60% “very much improved,” 20% “much improved,” 16% “minimally improved,” and 4% “no change.” Parkinsonism improved (Hoehn and Yahr: 1.76 ± 1.2 before vs. 1.04 ± 0.7 after, p < 0.001) as did dementia severity (Clinical Dementia Rating, p = 0.037). Adverse events included delirium in 24% of patients and amnesia in 4% of patients. ECT did not worsen cognitive function.Conclusions: ECT for DLB and MCI with LB with antecedent psychiatric symptoms appears safe and effective in managing psychiatric symptoms and Parkinsonism. Further large‐scale multicenter studies are warranted to conclusively establish its effectiveness and safety.


  • Difficulties in diagnosing phenoconversion to dementia in psychiatric‐onset prodromal dementia with Lewy bodies

    by Fumiyoshi Morikawa, Kazuki Tabata, Tomonori Murayama, Shota Fukuya, Jyuichiro Naoe


  • Open Access

    Development of a Novel Nutrition-Related Multivariate Biomarker for Mild Cognitive Impairment Based on the Plasma Free Amino Acid Profile

    by Takeshi Ikeuchi, Yuki Yano, Wataru Sato, Fumiyoshi Morikawa, Shuta Toru, Chika Nishimura, Nobuhiko Miyazawa, Yasuko Kuroha, Ryoko Koike, Shin Tanaka, et al.

    Nutritional epidemiology has shown the importance of protein intake for maintaining brain function in the elderly population. Mild cognitive impairment (MCI) may be associated with malnutrition, especially protein intake. We explored blood-based biomarkers linking protein nutritional status with MCI in a multicenter study. In total, 219 individuals with MCI (79.5 ± 5.7 year) from 10 institutions and 220 individuals who were cognitively normal (CN, 76.3 ± 6.6 year) in four different cities in Japan were recruited. They were divided into the training (120 MCI and 120 CN) and validation (99 MCI and 100 CN) groups. A model involving concentrations of PFAAs and albumin to discriminate MCI from CN individuals was constructed by multivariate logistic regression analysis in the training dataset, and the performance was evaluated in the validation dataset. The concentrations of some essential amino acids and albumin were significantly lower in MCI group than CN group. An index incorporating albumin and PFAA discriminated MCI from CN participants with the AUC of 0.705 (95% CI: 0.632–0.778), and the sensitivities at specificities of 90% and 60% were 25.3% and 76.8%, respectively. No significant association with BMI or APOE status was observed. This cross-sectional study suggests that the biomarker changes in MCI group may be associated with protein nutrition.